Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$11.9 million.

  • Enanta Pharmaceuticals' Income from Continuing Operations rose 4644.24% to -$11.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$71.4 million, marking a year-over-year increase of 3180.41%. This contributed to the annual value of -$81.8 million for FY2025, which is 2941.25% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Income from Continuing Operations of -$11.9 million as of Q4 2025, which was up 4644.24% from -$18.6 million recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Income from Continuing Operations peaked at -$11.9 million during Q4 2025, and registered a low of -$39.1 million during Q2 2023.
  • For the 5-year period, Enanta Pharmaceuticals' Income from Continuing Operations averaged around -$27.5 million, with its median value being -$28.4 million (2023).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 50391.34% in 2021, then soared by 4644.24% in 2025.
  • Enanta Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then fell by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then soared by 46.44% to -$11.9 million in 2025.
  • Its Income from Continuing Operations stands at -$11.9 million for Q4 2025, versus -$18.6 million for Q3 2025 and -$18.3 million for Q2 2025.